REGγ Mediated Regulation of p21Waf/Cip1, p16INK4a and p14ARF/p19ARF in Vivo


p21Waf/Cip1, p16INK4a and p14ARF (p19ARF in mice) have been demonstrated to be degraded by REGγ-proteasome pathway in an ATP- and ubiquitin-independent manner in vitro. However, the in vivo roles of REGγ mediated-degradation of p21Waf/Cip1, p16INK4a and p14ARF remain unclear. In this study, we showed enhanced expression of p21Waf/Cip1, p16INK4a and p19ARF in multiple tissues from REGg–/– mice compared to REGg+/+ mice. Furthermore, we examined the expression of p21Waf/Cip1, p16INK4a and p14ARF in different cancer tissues and observed that the REGγ protein levels were highly expressed in different human cancers while the level of p21Waf/Cip1, p16INK4a and p14ARF appears to be inversely correlated. These results demonstrate that REGγ may exert its function in physiological and pathological conditions through degradation of p21Waf/Cip1, p16INK4a and p14ARF in vivo.

Share and Cite:

L. Li, P. Zhang, H. Wei, W. Wang, L. Yao, Y. Li, L. Zhou, Z. Wang, J. Liu, L. Zhou, A. Amjad, B. Zhang, T. Jing, J. Xiao, Y. Dang and X. Li, "REGγ Mediated Regulation of p21Waf/Cip1, p16INK4a and p14ARF/p19ARF in Vivo," Journal of Cancer Therapy, Vol. 4 No. 5, 2013, pp. 933-938. doi: 10.4236/jct.2013.45104.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. E. Quelle, F. Zindy, R. A. Ashmun, et al., “Alternative Reading Frames of the INK4a Tumor Suppressor Gene Encode Two Unrelated Proteins Capable of Inducing Cell Cycle Arrest,” Cell, Vol. 83, No. 6, 1995, pp. 993-1000. doi:10.1016/0092-8674(95)90214-7
[2] S. W. Lowe and C. J. Sherr, “Tumor Suppression by INK4a-Arf: Progress and Puzzles,” Current Opinion in Genetics & Development, Vol. 13, No. 1, 2003, pp. 77-83. doi:10.1016/S0959-437X(02)00013-8
[3] M. Serrano, H. Lee, L. Chin, et al., “Role of the INK4a Locus in Tumor Suppression and Cell Mortality,” Cell, Vol. 85, No. 1, 1996, pp. 27-37. doi:10.1016/S0092-8674(00)81079-X
[4] P. Krimpenfort, K. C. Quon, W. J. Mooi, et al., “Loss of p16INK4a Confers Susceptibility to Metastatic Melanoma in Mice,” Nature, Vol. 413, No. 6851, 2001, pp. 83-86. doi:10.1038/35092584
[5] M. Serrano, G. J. Hannon and D. Beach, “A New Regulatory Motif in Cell-Cycle Control Causing Specific Inhibition of Cyclin D/CDK4,” Nature, Vol. 366, No. 6456, 1993, pp. 704-707. doi:10.1038/366704a0
[6] C. J. Sherr, “Principles of Tumor Suppression,” Cell, Vol. 116, No. 2, 2004, pp. 235-246. doi:10.1016/S0092-8674(03)01075-4
[7] E. Sharpless and L. Chin, “The INK4a/ARF Locus and Melanoma,” Oncogene, Vol. 22, No. 20, 2003, pp. 3092-3098. doi:10.1038/sj.onc.1206461
[8] R. Ben-Saadon, I. Fajerman, T. Ziv, et al., “The Tumor Suppressor Protein p16INK4a and the Human Papillomavirus Oncoprotein-58 E7 Are Naturally Occurring LysineLess Proteins That Are Degraded by the Ubiquitin System. Direct Evidence for Ubiquitination at the N-Terminal Residue,” The Journal of Biological Chemistry, Vol. 279, No. 40, 2004, pp. 41414-41421. doi:10.1074/jbc.M407201200
[9] S. Bates, A. C. Phillips, P. A. Clark, et al., “p14ARF Links the Tumour Suppressors RB and p53,” Nature, Vol. 395, No. 6698, 1998, pp. 124-125. doi:10.1038/25867
[10] I. Palmero, C. Pantoja and M. Serrano, “p19ARF Links the Tumour Suppressor p53 to Ras,” Nature, Vol. 395, No. 6698, 1998, pp. 125-126. doi:10.1038/25870
[11] A. Radfar, I. Unnikrishnan, H. W. Lee, et al., “p19ARF Induces p53-Dependent Apoptosis during Abelson VirusMediated Pre-B Cell Transformation,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, No. 22, 1998, pp. 13194-13199. doi:10.1073/pnas.95.22.13194
[12] F. Zindy, R. T. Williams, T. A. Baudino, et al., “ARF Tumor Suppressor Promoter Monitors Latent Oncogenic Signals in Vivo,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 100, No. 26, 2003, pp. 15930-15935. doi:10.1073/pnas.2536808100
[13] R. Honda, and H. Yasuda, “Association of p19ARF with Mdm2 Inhibits Ubiquitin Ligase Activity of Mdm2 for Tumor Suppressor p53,” The EMBO Journal, Vol. 18, No. 1, 1999, pp. 22-27. doi:10.1093/emboj/18.1.22
[14] C. A. Midgley, J. M. Desterro, M. K. Saville, et al., “An N-Terminal p14 ARF Peptide Blocks Mdm2-Dependent Ubiquitination in Vitro and Can Activate p53 in Vivo,” Oncogene, Vol. 19, No. 19, 2000, pp. 2312-2323.
[15] X. Li, D. M. Lonard, S. Y. Jung, et al., “The SRC-3/AIB1 Coactivator Is Degraded in a Ubiquitinand ATP-Independent Manner by the REGγ Proteasome,” Cell, Vol. 124, No. 2, 2006, pp. 381-392. doi:10.1016/j.cell.2005.11.037
[16] X. Chen, L. F. Barton, Y. Chi, et al., “Ubiquitin-Independent Degradation of Cell-Cycle Inhibitors by the REGγ Proteasome,” Molecular Cell, Vol. 26, No. 6, 2007, pp. 843-852. doi:10.1016/j.molcel.2007.05.022
[17] X. Li, L. Amazit, W. Long, et al., “Ubiquitinand ATPIndependent Proteolytic Turnover of p21 by the REGgamma-Proteasome Pathway,” Molecular Cell, Vol. 26, No. 6, 2007, pp. 831-842. doi:10.1016/j.molcel.2007.05.028
[18] T. Okamura, S. Taniguchi, T. Ohkura, et al., “Abnormally High Expression of Proteasome Activator-Gamma in Thyroid Neoplasm,” The Journal of Clinical Endocrinology & Metabolism, Vol. 88, No. 3, 2003, pp. 1374-1383.
[19] M. Roessler, W. Rollinger, L. Mantovani-Endl, et al., “Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by Combining Two-Dimensional Polyacrylamide Gel Electrophoresis with a Strictly Mass Spectrometry-Based Approach for Data Analysis,” Molecular & Cellular Proteomics, Vol. 5, No. 11, 2006, pp. 2092-2101. doi:10.1074/mcp.M600118-MCP200
[20] Y. Hong, K. S. Ho, K. W. Eu, et al., “A Susceptibility Gene Set for Early Onset Colorectal Cancer That Integrates Diverse Signaling Pathways: Implication for Tumorigenesis,” Clinical Cancer Research, Vol. 13, No. 4, 2007, pp. 1107-1114. doi:10.1158/1078-0432.CCR-06-1633
[21] H. L. Jia, Q. H. Ye, L. X. Qin, et al., “Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma,” Clinical Cancer Research, Vol. 13, No. 4, 2007, pp. 1133-1139. doi:10.1158/1078-0432.CCR-06-1025
[22] J. He, L. Cui, Y. Zeng, et al., “REGγ Is Associated with Multiple Oncogenic Pathways in Human Cancers,” BMC Cancer, Vol. 12, 2012, p. 75. doi:10.1186/1471-2407-12-75
[23] G. Yu, Y. Zhao, J. He, et al., “Comparative Analysis of REGγ Expression in Mouse and Human Tissues,” Journal of Molecular Cell Biology, Vol. 2, No. 4, 2010, pp. 192-198. doi:10.1093/jmcb/mjq009
[24] G. Salvatore, T. C. Nappi, P. Salerno, et al., “A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma,” Cancer Research, Vol. 67, No. 21, 2007, pp. 10148-10158. doi:10.1158/0008-5472.CAN-07-1887
[25] Y. Zhang, Y. Xiong and W. G. Yarbrough, “ARF Promotes MDM2 Degradation and Stabilizes p53: ARFINK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways,” Cell, Vol. 92, No. 6, 1998, pp. 725-734. doi:10.1016/S0092-8674(00)81401-4
[26] L. F. Barton, H. A. Runnels, T. D. Schell, et al., “Immune Defects in 28-kDa Proteasome Activator Gamma-Deficient Mice,” The Journal of Immunology, Vol. 172, No. 6, 2004, pp. 3948-3954.
[27] I. Mao, J. Liu, X. Li, et al., “REGγ, a Proteasome Activator and beyond?” Cellular and Molecular Life Sciences, Vol. 65, No. 24, 2008, pp. 3971-3980. doi:10.1007/s00018-008-8291-z
[28] Z. Zhang and R. Zhang, “Proteasome Activator PA28 Gamma Regulates p53 by Enhancing Its MDM2-Mediated Degradation,” The EMBO Journal, Vol. 27, No. 6, 2008, pp. 852-864. doi:10.1038/emboj.2008.25

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.